$FORR

Compared to Estimates, Forrester Research (FORR) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Forrester Research (FORR) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Oct 30, 2025, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 31, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Compared to Estimates, Forrester Research (FORR) Q3 Earnings: A Look at Key Metrics — source image
Decision brief

The 30-second read

$FORRNeutralLow
01

Why it matters

The earnings results suggest cautious optimism; while revenue met expectations, slight EPS shortfalls may temper investor enthusiasm.

02

Market read

The news has limited immediate impact on the broader market but is relevant for sector-specific traders and investors.

03

What to watch

Broader economic conditions and upcoming industry trends could influence future performance beyond this earnings report.

Relevance 6/10Timing: short-term (immediate to 1 week)

Background

Forrester Research reported its Q3 2025 earnings, providing an update on its financial health amid ongoing industry challenges.

Company-level read

Ticker impact

$FORRNeutralMedium confidence
Context

The news discusses Forrester Research's Q3 2025 earnings compared to estimates, providing insights into its recent financial performance.

Expected impact

Minimal immediate price movement; potential for slight volatility based on earnings sentiment.

Evidence & confidence

The earnings report aligns with analyst expectations, suggesting limited short-term price impact. However, slight deviations in EPS could cause minor fluctuations.

Market effects

The technology and consulting sector may experience minor adjustments based on earnings trends of firms like FORR.

Limited regional impact; primarily relevant to US markets.

Low; Forrester's earnings are more sector-specific and do not significantly influence global markets.

Counterpoint

Some investors might interpret the stable earnings as a sign of resilience, potentially supporting a bullish outlook.

Key entities

  • Forrester Research

    A leading research and advisory firm specializing in technology and marketing insights.

Related articles

$FORRMedAI 8/10

Forrester (FORR) Q2 2026 Earnings Call Transcript

Thursday, July 30, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer and Chairman - George F. Colony Chief Financial Officer - Leo Christian Finn Vice President of Corporate Development, and Investor Relations - Ed Bryce Morris Chief Product Officer - Carrie Johnson Fanlo Chief Sales Officer - Christophe Favre TAKEAWAYS Total Revenue -- Forrester Research, Inc.

$FORRHigh

Forrester Research Reports 2026 Second-Quarter Financial Results

FORRESTER RESEARCH, INC. (FORR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Forrester Research Reports 2026 Second-Quarter Financial Results CAMBRIDGE, Mass., July 30, 2026 — Forrester Research, Inc. (Nasdaq: FORR) today announced financial results for the second quarter ended June 30, 2026, with contract value at $283.

$GMABMedAI 8/10

Genmab reports trial results for ovarian cancer drug candidate

Genmab (GMAB) reported Phase 1/2 trial results for rinatabart sesutecan in platinum-resistant ovarian cancer, showing a 45.9% response rate and median progression-free survival of 9.5 months. The trial involved 109 patients, with common side effects including fatigue, nausea, and anemia. The drug is being evaluated in four Phase 3 trials for various gynecologic cancers.

$RKLBMed

Rocket Lab Just Signed the Biggest Commercial Electron Deal in Its History. Its Launch Backlog Now Tops 100.

Rocket Lab (RKLB) secured a 20-launch deal with Synspective, its largest commercial contract, boosting its backlog to over 100 missions. Synspective's total orders now reach 47 Electron missions. The stock rose 6% post-announcement, but concerns about competition from SpaceX persist. Rocket Lab's revenue per launch increased to $9.2M in H1 2026, with costs dropping to $4.9M.